Ostrowiec Swietokrzyski

• An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation
  2024-510810-33-00 5 2024-10-14 Severe eosinophilic asthma
• Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Not authorised
  2023-503522-40-00 4 Atopic Dermatitis
• Study to Evaluate the Efficacy and Safety of ATI-045 in Atopic Dermatitis Not authorised
  2024-520302-19-00 4 Atopic dermatitis
• Efficacy, safety, and tolerability study of lunsekimig compared with placebo in adult participants with inadequately controlled chronic obst … Pending
  2024-518213-25-00 10 Respiratory tract diseases
• A Study to Learn About the Study Medicine Called PF-07275315 in Adults with Moderate-To-Severe Long-Term Breathing Difficulty, Known by the … Pending
  2024-518587-12-00 4 MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
• Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending
  2024-518821-13-00 4 Non-cystic Fibrosis Bronchiectasis
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo Pending
  2025-524726-18-00 4 Non-Segmental Vitiligo (NSV)
• A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) Pending
  2025-524727-41-00 4 Alopecia Areata
• Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting
  2025-522896-27-00 4 2026-05-11 Asthma
• A Long-Term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older with Moderate to Severe Eczema Recruiting
  2023-509124-18-00 5 2025-12-19 Moderate-to-Severe Atopic Dermatitis
• A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm … Recruiting
  2025-521268-37-00 6 2025-11-25 Respiratory tract diseases
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag … Recruiting
  2023-503630-44-00 10 2024-11-20 Treatment of moderate-to-severe Atopic dermatitis
• A Phase 3 Study With Randomized Withdrawal/Dose Up Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants With … Recruiting
  2023-505804-42-00 5 2024-07-10 NON SEGMENTAL VITILIGO
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa Recruiting
  2025-522440-41-00 4 2026-04-27 Hidradenitis Suppurativa
• A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medic … Recruiting
  2025-522705-37-00 4 2026-04-21 HIDRADENITIS SUPPURATIVA
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 4 2026-04-13 Mild to moderate asthma
• Phase 2b study of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus (RSV) who are at high risk of progression … Recruiting
  2025-523156-31-00 4 2026-03-17 Respiratory Syncytial Virus
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo … Recruiting
  2025-520499-24-00 5 2025-10-01 Moderate to Severe Platysma Prominence
• A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age with Moderate-to-Severe Atopic Eczema Recruiting
  2023-509121-51-00 5 2025-09-30 Moderate-to-Severe Atopic Dermatitis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult … Recruiting
  2023-505218-68-00 4 2025-06-12 Moderate-Severe Atopic Dermatitis

Showing 1–24 of 79 trials